Vigil Neuroscience, Inc. (VIGL)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
The mean of analysts' price targets for Vigil Neuroscience (VIGL) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical perspective. VIGL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know
Vigil Neuroscience (VIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer's disease.
Vigil Neuroscience initiated with an Outperform at William Blair
William Blair analyst Sarah Schram initiated coverage of Vigil Neuroscience with an Outperform rating.
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each.
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
